US Stock MarketDetailed Quotes
NMRA Neumora Therapeutics
- 10.850
- +0.350+3.33%
Close Dec 20 16:00 ET
- 10.360
- -0.490-4.52%
Post 20:01 ET
1.75BMarket Cap9.77P/E (TTM)
11.100High10.073Low1.90MVolume10.170Open10.500Pre Close20.59MTurnover2.24%Turnover RatioLossP/E (Static)161.56MShares21.00052wk High5.47P/B921.38MFloat Cap8.33052wk Low--Dividend TTM84.92MShs Float21.000Historical High--Div YieldTTM9.78%Amplitude8.330Historical Low10.812Avg Price1Lot Size
Neumora Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 29.91%-33.48M | -81.03%-56.16M | -30.01%-42.96M | -42.11%-163.28M | -69.41%-51.44M | -85.43%-47.77M | -16.71%-31.02M | -2.66%-33.04M | -52.34%-114.9M | -3.45%-30.37M |
| Net income from continuing operations | -36.81%-72.55M | -52.30%-58.7M | -50.80%-53.72M | -80.23%-235.93M | -286.31%-108.73M | -80.71%-53.03M | -26.90%-38.54M | 17.23%-35.63M | 44.84%-130.9M | -4.36%-28.15M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -988.68%-577K | ---316K |
| Depreciation and amortization | -9.83%156K | -6.43%160K | 0.00%158K | 12.46%668K | 12.93%166K | 18.49%173K | 11.04%171K | 7.48%158K | 10.41%594K | 12.21%147K |
| Other non cash items | -0.58%854K | -4.47%812K | -2.83%791K | 338.98%67.38M | 8,017.15%64.86M | -16.44%859K | 181.46%850K | -93.84%814K | -90.29%15.35M | -0.50%799K |
| Change In working capital | 2,567.23%29.43M | -277.22%-9.03M | 1,062.14%3.59M | -28.08%-8.9M | -153.27%-13.11M | -314.95%-1.19M | 194.62%5.1M | 107.62%309K | -623.00%-6.95M | -15.56%-5.18M |
| -Change in prepaid assets | 356.79%17.69M | -129.56%-9.74M | -6.45%7.35M | -214.25%-11.4M | -293.18%-8.13M | -642.46%-6.89M | -3,219.12%-4.24M | 1,121.85%7.86M | -60.53%-3.63M | 8.98%-2.07M |
| -Change in payables and accrued expense | 91.93%12.6M | -84.97%1.53M | 56.16%-2.96M | 305.96%5.91M | -203.85%-4.07M | 207.69%6.57M | 466.28%10.16M | 37.03%-6.75M | -149.41%-2.87M | 133.39%3.92M |
| -Change in other current assets | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | 137.48%1.37M | -72.46%-6.25M |
| -Change in other current liabilities | 0.92%-861K | -0.24%-822K | -0.12%-802K | -86.36%-3.4M | -16.90%-913K | -44.35%-869K | -310.00%-820K | -229.63%-801K | -117.12%-1.83M | -194.72%-781K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 29.91%-33.48M | -81.03%-56.16M | -30.01%-42.96M | -42.11%-163.28M | -69.41%-51.44M | -85.43%-47.77M | -16.71%-31.02M | -2.66%-33.04M | -52.34%-114.9M | -3.45%-30.37M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 559.20%156.99M | -11.72%21.26M | -5,424.85%-150M | 138.32%64.39M | 270.32%13.68M | 42.66%23.82M | 126.44%24.08M | 103.29%2.82M | -20,464.63%-168.01M | -4,171.28%-8.03M |
| Net PPE purchase and sale | --0 | --0 | --0 | 77.10%-117K | -91.30%-44K | 71.54%-37K | --0 | 79.55%-36K | 37.45%-511K | 87.77%-23K |
| Net investment purchase and sale | 558.18%156.99M | -11.72%21.26M | -5,330.49%-149.23M | 144.72%69.09M | 328.69%18.31M | 41.78%23.85M | 126.49%24.08M | 103.94%2.85M | ---154.5M | ---8.01M |
| Net other investing changes | --0 | --0 | ---775K | 64.69%-4.59M | ---- | ---- | ---- | ---- | ---13M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 559.20%156.99M | -11.72%21.26M | -5,424.85%-150M | 138.32%64.39M | 270.32%13.68M | 42.66%23.82M | 126.44%24.08M | 103.29%2.82M | -20,464.63%-168.01M | -4,171.28%-8.03M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -99.34%1.53M | 808.90%2.65M | 1,726.73%1.85M | 100.39%231.94M | -101.79%-481K | 166.15%232.02M | -85.98%292K | 128.77%101K | -60.57%115.74M | 7,595.25%26.83M |
| Net common stock issuance | ---- | ---- | ---- | --232.88M | ---491K | ---- | ---- | ---- | --0 | --0 |
| Net preferred stock issuance | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -61.46%112.22M | 39,738.10%24.97M |
| Proceeds from stock option exercised by employees | 16.21%1.76M | 556.93%2.65M | 1,562.16%1.85M | -33.13%2.86M | -49.85%830K | 949.31%1.51M | -82.50%404K | -32.32%111K | 70.23%4.27M | 95.63%1.66M |
| Net other financing activities | ---- | ---- | ---- | -411.29%-3.8M | -498.06%-820K | -1,262.86%-2.86M | 50.22%-112K | 98.06%-10K | 34.79%-744K | --206K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -99.34%1.53M | 808.90%2.65M | 1,726.73%1.85M | 100.39%231.94M | -101.79%-481K | 166.15%232.02M | -85.98%292K | 128.77%101K | -60.57%115.74M | 7,595.25%26.83M |
| Net cash flow | ||||||||||
| Beginning cash position | -26.06%151.89M | -13.18%184.14M | 54.93%375.25M | -40.83%242.21M | 62.94%413.5M | 16.95%205.43M | -27.18%212.08M | -40.83%242.21M | 113.10%409.37M | -42.23%253.77M |
| Current changes in cash | -39.91%125.04M | -384.80%-32.25M | -534.44%-191.11M | 179.59%133.05M | -230.76%-38.25M | 166.39%208.07M | 94.24%-6.65M | 74.50%-30.12M | -176.94%-167.17M | 61.33%-11.56M |
| End cash Position | -33.03%276.93M | -26.06%151.89M | -13.18%184.14M | 54.93%375.25M | 54.93%375.25M | 62.94%413.5M | 16.95%205.43M | -27.18%212.08M | -40.83%242.21M | -40.83%242.21M |
| Free cash flow | 29.97%-33.48M | -81.03%-56.16M | -29.86%-42.96M | -41.58%-163.4M | -69.42%-51.49M | -84.64%-47.81M | -15.92%-31.02M | -2.21%-33.08M | -51.38%-115.41M | -2.87%-30.39M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Heat List
US
Overall
Symbol
Price
% Chg
No Data